Zepbound (tirzepatide) is a medication classified as a GIP and GLP-1 receptor agonist. It is prescribed for weight loss in adults dealing with obesity or those who are overweight and have weight-related medical issues. When used in conjunction with a balanced diet and regular exercise, Zepbound aids in weight reduction and helps maintain the achieved weight loss.
The mechanism of Zepbound involves reducing appetite and slowing the movement of food from the stomach to the small intestine. This, in turn, can create a sensation of fullness more quickly and for an extended period.
Administered through a once-weekly injection under the skin (subcutaneously) using a pre-filled single-dose pen, Zepbound shares the active ingredient tirzepatide with Mounjaro, both manufactured by Eli Lilly and Company. As a GIP and GLP-1 receptor agonist, Zepbound activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Zepbound gained approval from the FDA on November 8, 2023, specifically for chronic weight management in adults with obesity (BMI of 30 kg/m2 or greater) or those who are overweight (BMI of 27 kg/m2 or greater) and also have weight-related medical conditions like hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease. Its usage is recommended alongside a balanced diet and increased physical activity.
Regarding weight loss outcomes, participants in the clinical trial SURMOUNT-1 (NCT04184622) experienced significant weight reductions over 72 weeks. For those on a 5mg weekly dose of Zepbound, the average weight loss was 16.1 kg (35.5 lb). The 10mg weekly dose resulted in an average weight loss of 22.2 kg (48.9 lb), and the 15mg weekly dose led to an average weight loss of 23.6 kg (52.0 lb). In comparison, individuals on a placebo lost an average of 2.4 kg (5.3 lb) over the same period. It’s essential to note that individual results may vary.